Navigation Links
MAP Pharmaceuticals, Inc. Prices Public Offering of Common Stock
Date:8/1/2012

on in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About MAP Pharmaceuticals

MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine.

Forward-Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to our expectations regarding the completion of the public offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to the satisfaction of customary closing conditions related to the public offering and the impact of general economic, industry or political conditions in the United States or internationally. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Additional risks and uncertainties relating to the public offering, MAP Pharmaceuticals and our business can be found under the heading "Risk Factors" in our most recent Form 10-Q filed with the SEC, in other filings that we periodically make with the SEC, and in the prospectus supplement related to the offering to be filed with the SEC. In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statem
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Announces Second Quarter 2012 Financial Results
2. Jason Pharmaceuticals, Inc. Reaches Proposed Consent Agreement with FTC
3. Avion Pharmaceuticals, LLC., Launches Prenate Mini
4. AcelRx Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
5. AcelRx Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com on July 12th
6. Acella Pharmaceuticals, LLC, files Abbreviated New Drug Application (ANDA) With the U.S. Food & Drug Administration for Topical Corticosteroids Lotion
7. Law Office of Brodsky & Smith, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Bristol-Myers Squibb Company
9. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
10. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
11. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 2013  Recent regulatory and budget challenges have made ... at large pharmaceutical companies to effectively educate doctors and ... of their new products. With the pressure to reduce ... that these "Med Ed" groups find practical, ... address the changes that are transforming the Medical Education ...
(Date:6/18/2013)... , June 18, 2013 Unilife Corporation ... based designer, developer and manufacturer of injectable drug delivery ... website at www.unilife.com . The new site includes ... updates to occur on a regular basis. ... stated, "As an emerging global leader for injectable drug ...
(Date:6/18/2013)... , June 18, 2013  Specialty ... significant breakthrough in Parylene coating technologies: SCS ... the benefits of Parylene with antimicrobial properties ... devices and components. (Logo: ... infections (HAIs) increase and continue to pose ...
Breaking Medicine Technology:Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2Unilife Launches New Corporate Website 2Specialty Coating Systems Announces New Antimicrobial Parylene Technology 2
... All pre-specified subset analyses of progression-free survival,in the ... in,relative risk of disease progression for patients receiving,satraplatin. ... as presence or absence of pain. -- The ... - radiologic,progression and pain progression - were each ...
... ,Abstracts: 2000, 2002 , CHICAGO/DARMSTADT, Germany, June 4, ... today at the American Society of,Clinical Oncology (ASCO) ... cilengitide in patients with newly diagnosed,glioblastoma – a ... highly selective integrin inhibitor targeting the,tumor and its ...
Cached Medicine Technology:Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 2Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 3Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 4Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 5
(Date:6/19/2013)... 2013 At a Travel Services Member Conference, ... growth that has occurred over the last year since he ... said, "Travel Services has added vendors, lowered prices of travel ... Membership is up, even in the tough economy, and they've ... members." , Having been in the Travel Business and Timeshare ...
(Date:6/19/2013)... The motor neuron disease Amyotrophic lateral sclerosis (ALS), also ... sequential pattern which can be classified into four distinct ... at the University of Pennsylvania in the Annals ... and spinal cord tissues shows, for the first time, ... starting point in the central nervous system to other ...
(Date:6/19/2013)... from a naturally occurring compound (apocynin), has been ... Parkinson,s Disease symptoms by preventing deficits in motor ... May 28, 2013 edition of Neuroscience ... fellow at the Medical College of Wisconsin (MCW), ... Balaraman Kalyanaraman, Ph.D., Harry R. & Angeline E. ...
(Date:6/19/2013)... Imprivata ®, a leading global provider ... Imprivata OneSign ® leads the single sign-on (SSO) category ... & Services report . CIOs and other healthcare executives ... performance of its products and the quality of its ... is integral to their long-term healthcare IT strategy. ...
(Date:6/19/2013)... 19, 2013 The US Food and Drug ... ultra cohesive gel breast implant, Mentor Worldwide’s MemoryShape™. , The ... February 2013. The FDA announced the approval of the MemoryShape™ ... primary augmentations in women 22 years old or ... , The FDA’s approval comes after six years of ...
Breaking Medicine News(10 mins):Health News:Former Owner Eric Shuman Endorses New Owners and Changes Made in Last Year Since Shuman Sold Travel Services Center at Member Conference 2Health News:Staging system in ALS shows potential tracks of disease progression, Penn study finds 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3Health News:FDA Approved Mentor® MemoryShape™ Breast Implants Now Offered to Patients at Swan Center for Plastic Surgery 2
... between the ages of 40 and 59 could substantially reduce ... the September 9 online issue of the Journal of ... are regularly used in developed countries where the incidence of ... is in place. The value and practicality of such screening ...
... ARBOR, Mich.---Pregnant women who take high levels of daily calcium ... blood, suggesting calcium could play a critical role in reducing ... University of Michigan shows that women who take 1,200 milligrams ... in lead levels. , Women who used lead-glazed ceramics and ...
... still giving them to new moms , , TUESDAY, Sept. ... the majority of East Coast hospitals report giving formula ... medical organizations oppose this practice. , The study, ... of Pediatrics & Adolescent Medicine , surveyed 1,295 ...
... Physician Recruitment Firm Will Grow Through Leadership Development and ... ... Alpharetta, Ga. (Vocus) September 9, 2008 -- ... Jackson president of Alpharetta, Ga.-based http://www.locumtenens.com/new_leader08 [LocumTenens.com]. ...
... that sugar,makes good foods taste better, helps breads rise, ... jams and jellies. But,did you know the same preserving ... heal wounds?, Sugar is one of Mother Nature,s ... sugar an excellent food preservative also bestow,it with its ...
... may be better able to comply with medication regimens ... tables that track what they take and when they ... "medtable" may help to prevent medication-related problems. A report ... Experimental Psychology: Applied, published by the American ...
Cached Medicine News:Health News:Breast cancer screening may lower mortality and disease burden in India 2Health News:Calcium during pregnancy reduces harmful blood lead levels 2Health News:Formula Samples Hinder Breast-Feeding Efforts 2Health News:R. Shane Jackson Named President of LocumTenens.com 2Health News:R. Shane Jackson Named President of LocumTenens.com 3Health News:Sugar's Healing Powers 2Health News:Older adults can take medicines more safely and effectively by charting their daily routines 2Health News:Older adults can take medicines more safely and effectively by charting their daily routines 3
... a 60 watt diode continuous wave laser with ... Power Bar technology and 940 nm wavelength make ... for varicose veins and a variety of surgical ... safety features including the LPS, Light guide Protection ...
... is an instrument and LIS independent connectivity ... to work more efficiently than ever. It ... solution that stands between instrument or medical ... important gaps in functionality between the two, ...
70 discs to investigate acquired color deficiency. Quantifies neutral zone characteristics of dyschromatopsia and evaluates the relative luminance....
... the Farnsworth 100 Hue Test comes boxed in ... reduces the potential for test disruption by ... 100 Hue test from Richmond Products includes 93 ... a durable laminated score template for copying, a ...
Medicine Products: